Julin J E, van Burik J H, Krivit W, Webb C, Holman C J, Clark H B, Balfour H H
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Transpl Infect Dis. 2002 Dec;4(4):201-6. doi: 10.1034/j.1399-3062.2002.02005.x.
A 20-year-old patient, who received a bone marrow transplant in order to treat metachromatic leukodystrophy (MLD), succumbed to cytomegalovirus (CMV) encephalitis. After CMV viremia developed, the patient received ganciclovir, but he was switched to foscarnet when ganciclovir resistance was suspected. Foscarnet was discontinued because of concern about its potential central nervous system toxicity. Autopsy samples of brain and cerebrospinal fluid contained CMV DNA with a UL97 mutation (M460V) known to confer ganciclovir resistance. No foscarnet resistance mutations were found.
一名20岁的患者为治疗异染性脑白质营养不良(MLD)接受了骨髓移植,最终死于巨细胞病毒(CMV)脑炎。在出现CMV病毒血症后,该患者接受了更昔洛韦治疗,但在怀疑出现更昔洛韦耐药后改用了膦甲酸钠。由于担心膦甲酸钠潜在的中枢神经系统毒性,停用了膦甲酸钠。脑和脑脊液的尸检样本中含有CMV DNA,带有已知可导致更昔洛韦耐药的UL97突变(M460V)。未发现膦甲酸钠耐药突变。